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Background:  
Parathyroid carcinoma (PCa) is a rare presentation of primary hyperparathyroidism (PHPT), accounting for less than 1 % of cases. Differentiating 
parathyroid cancer from benign hyperparathyroidism is clinically challenging. Some previous work suggest paraneoplastic hCG production in 
parathyroid cancer (Stock et al 1987, Rubin et al 2008). In this study, we aimed to investigate whether the hCG+β kit from Roche Diagnostics could 
distinguish PCa patients from primary and secondary hyperparathyroidism. Additionally, we validate hCG levels according to renal function and 
determine hCG test sensibility and specificity to diagnose parathyroid cancer. 
 
Material and methods: 
We studied a series of 8 patients suffering from advanced PCa, referred to the CHU de Liege. A control group of 20 PHPT patients and 25 patients with 
chronic renal failure and secondary hyperparathyroidism (SHP) were used as comparative. hCG+β kit on Cobas (Roche Diagnostics) uses 2 monoclonal 
antibodies that recognize holo-hCG, nicked hCG, β-core fragment and free β-subunit. Limits of hCG detection and quantification are <0.1 and <0.6 
mUI/mL. In non pregnant and postmenopausal women and in men, hCG (p95) is <1 (5.3), <7 mUI/mL (8.3) and <2 (2.6) mUI/mL, respectively.  
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Conclusions:  
These results suggest that serum hCG might have the potential to discriminate between parathyroid adenomas and carcinomas, with a sensibility of 
75% and a specificity of 94, and a cut off of 5.68 mUI/L. The only patient still alive presented the lowest hCG values. If hCG could be predictive of PCa 
survival needs to be studied in a larger series of patients. A future area of research revealed by this data is to investigate the results of  hCG 
immunotherapy in parathyroid cancer.  
Results:  
The eight PCa patients (3 women) presented high serum hCG values at: 1.29, 3.46, 5.7, 24.2, 31.2, 34.1, 36.5 and 164 mUI/mL. Values of 1.29 and 3.46 
were obtained in 2 postmenopausal women. The lowest value was presented by the only still alive patient. In cancer patients, there was a significant 
correlation (r=0.786; ρ <0.05) between hCG and PTH and median hCG (5.7 mUI/ml)  was significantly higher than in PHP (1.25 mUI/ml) and SHP (0.97 
mUI/ml). hCG test sensitivity was 75 %  and specificity was 94% to detect parathyroid cancer, with a cutt off hCG levels of more than 5.68 mUI/. 
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